Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts its partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.

METHODS: Monocytes were freshly prepared from human blood samples. Cells were cultured with anti-IgM immunoglobulin (5 μg/ml) and Teneliximab (BMS 224819) (5 μg/ml). The effect on cell proliferation was further evaluated.
RESULTS Teneliximab (BMS 224819) promoted the proliferation of stimulated B cells. [1]

METHODS: Crab monkey groups were immunized with SRBC and received a single intravenous dose of Teneliximab (BMS 224819) at 10, 40, or 100 mg/kg to observe the ability of Teneliximab (BMS 224819) to inhibit primary Ab responses in vivo.
RESULTS Significant inhibition of the primary humoral immune response to SRBC by Teneliximab (BMS 224819) was observed at all three dose levels. [1]

Human

Monoclonal

Unconjugated